Items where authors include "Drayson, M."

Article

Masoud, S., Wong, K., Pitcher, D. et al. (269 more authors) (2025) Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis using the United Kingdom RaDaR Registry. Kidney International, 108 (3). pp. 455-469. ISSN 0085-2538

Beer, S.A., Cairns, D.A. orcid.org/0000-0002-2338-0179, Pawlyn, C. et al. (15 more authors) (2025) Challenging the Concept of Functional High-Risk Myeloma through Transcriptional and Genetic Profiling. Blood. ISSN 0006-4971 (In Press)

Masoud, S., Wong, K., Pitcher, D. et al. (268 more authors) (2025) Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranous proliferative glomerulonephritis using the United Kingdom RaDaR Registry. Kidney International. ISSN 0085-2538

Wong, K., Pitcher, D., Braddon, F. et al. (299 more authors) (2024) Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort. Kidney International Reports, 9 (7). pp. 2067-2083. ISSN 2468-0249

Wong, K., Pitcher, D., Braddon, F. et al. (299 more authors) (2024) Description and cross-sectional analyses of 25,880 adults and children in the UK National Registry of rare kidney diseases cohort. Kidney International Reports, 9 (7). pp. 2067-2083. ISSN 2468-0249

Wong, K., Pitcher, D., Braddon, F. et al. (294 more authors) (2024) Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort. The Lancet, 403 (10433). pp. 1279-1289. ISSN 0140-6736

Wong, K., Pitcher, D., Braddon, F. et al. (294 more authors) (2024) Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort. The Lancet, 403 (10433). pp. 1279-1289. ISSN 0140-6736

Agarwal, G., Moore, S., Sadler, R. et al. (21 more authors) (2024) Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma. Haematologica. ISSN 0390-6078

Twumasi, C. orcid.org/0000-0001-6817-8356, Moore, S. orcid.org/0000-0003-1380-1934, Sadler, R. orcid.org/0000-0003-2250-670X et al. (20 more authors) (2023) Determinants of durable humoral and T cell immunity in myeloma patients following <scp>COVID</scp>‐19 vaccination. European Journal of Haematology. ISSN 0902-4441

Proceedings Paper

Dawkins, B., Gkountouras, G., Meads, D. et al. (21 more authors) (2024) Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07-10 Dec 2024, San Diego, USA. American Society of Hematology , pp. 385-386.

Cook, G., Pawlyn, C., Royle, K.-L. et al. (20 more authors) (2024) IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07 Dec 2024, San Diego, USA. American Society of Hematology , pp. 673-674.

Pawlyn, C., Davies, F.E., Cook, G. orcid.org/0000-0001-7196-7364 et al. (16 more authors) (2024) Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial. In: Blood. The 66th ASH Annual Meeting, 07-10 Dec 2024, San Diego, USA. American Society of Hematology , pp. 1987-1988.

Reed, M., Cairns, D.A. orcid.org/0000-0002-2338-0179, Pawlyn, C. et al. (13 more authors) (2023) The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial. In: Blood. 65th ASH Annual Meeting and Exposition, 09-12 Dec 2023, San Diego, USA. American Society of Hematology , pp. 3366-3368.

Cook, G., Ashcroft, A.J., Senior, E.R. et al. (16 more authors) (2023) Ixazomib-based consolidation and maintenance prolongs progression-free survival after salvage autologous stem cell transplantation (sASCT): Results from interim analysis of UK-MRA myeloma XII (ACCoRD). In: Blood. 65th ASH Annual Meeting, 09-12 Dec 2023, San Diego, California, USA. American Society of Hematology , p. 783.

Jiang, Y., Down, J., Raffles, S. et al. (6 more authors) (2018) Targeting free light chain (FLC) secretion and the unfolded protein response in myeloma cells using VaN, a combination of repurposed drugs. In: Experimental Hematology. 47th Annual Scientific Meeting of the ISEH - International Society for Experimental Hematology, 23-26 Aug 2018, Los Angeles, USA. Elsevier , S74-S75.